Přejít k obsahu
Merck
Všechny fotografie(1)

Hlavní dokumenty

AB1258

Sigma-Aldrich

Anti-Cytochrome P450 Enzyme CYP1A1 Antibody

serum, Chemicon®

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

rabbit

Quality Level

antibody form

serum

antibody product type

primary antibodies

clone

polyclonal

species reactivity

human

manufacturer/tradename

Chemicon®

technique(s)

immunohistochemistry: suitable
western blot: suitable

NCBI accession no.

UniProt accession no.

shipped in

dry ice

target post-translational modification

unmodified

Gene Information

human ... AHRR(57491)

Specificity

Reacts with human cytochrome P450 CYP1A1 in human placental microsomal fraction and to recombinant human CYP1A1.

Immunogen

Synthetic peptide

Application

Anti-Cytochrome P450 Enzyme CYP1A1 Antibody detects level of Cytochrome P450 Enzyme CYP1A1 & has been published & validated for use in IH & WB.
Research Category
Metabolism
Research Sub Category
Enzymes & Biochemistry
Western blot

Immunohistochemistry

Optimal working dilutions must be determined by end user.

Linkage

Replaces: MAB3522

Physical form

Rabbit antiserum. Liquid, no preservatives.

Storage and Stability

Maintain at -20°C in undiluted aliquots for up to 12 months. Avoid repeated freeze/thaw cycles.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Ještě jste nenalezli správný produkt?  

Vyzkoušejte náš produkt Nástroj pro výběr produktů.

Storage Class

10 - Combustible liquids

wgk_germany

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable


Osvědčení o analýze (COA)

Vyhledejte osvědčení Osvědčení o analýze (COA) zadáním čísla šarže/dávky těchto produktů. Čísla šarže a dávky lze nalézt na štítku produktu za slovy „Lot“ nebo „Batch“.

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

D C Koch et al.
Oncogene, 34(50), 6092-6104 (2015-04-14)
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor and a member of the basic helix-loop-helix PER/ARNT/SIM family of chemosensors and developmental regulators. The AhR is widely known as a mediator of dioxin toxicity; however, it also suppresses cancer
Mingli Su et al.
Oncology letters, 14(6), 8100-8105 (2018-01-19)
3'3-Diindolylmethane (DIM) has been proved to exhibit anticancer properties in many solid tumors. In our previous study, we demonstrated that DIM inhibited SGC7901 cell proliferation by inducing apoptosis and delaying cell cycle progression. Herein, we further explored the anti-tumor effect
Tie-Li Peng et al.
World journal of gastroenterology, 15(14), 1719-1729 (2009-04-11)
To determine the functional significance of aryl hydrocarbon receptor (AhR) in gastric carcinogenesis, and to explore the possible role of AhR in gastric cancer (GC) treatment. RT-PCR, real-time PCR, and Western blotting were performed to detect AhR expression in 39
Xiao-Fei Yin et al.
Journal of experimental & clinical cancer research : CR, 31, 46-46 (2012-05-18)
Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor associated with gastric carcinogenesis. 3,3'-Diindolylmethane (DIM) is a relatively non-toxic selective AhR modulator. This study was to detect the effects of DIM on gastric cancer cell growth. Gastric cancer cell SGC7901
De Lin et al.
The Journal of pharmacology and experimental therapeutics, 363(1), 12-19 (2017-09-09)
Ponatinib, a pan-BCR-ABL tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia (CML), causes severe side effects including vascular occlusions, pancreatitis, and liver toxicity, although the underlying mechanisms remain unclear. Modifications of critical proteins through reactive metabolites are thought

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.